IntrinsicIntrinsic
← All summaries

ANAPTYSBIO, INC

ANAB
Financials & Chart →

Business Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases . The company's core business model involves generating revenue through financial collaborations, including milestones and royalties from out-licensed therapeutic antibodies, and license and transition services revenue from other collaborations . Primary customer segments for its out-licensed products are large biopharmaceutical companies like GSK and Vanda Pharmaceuticals Inc. .

The company's wholly-owned clinical-stage pipeline includes rosnilimab, ANB033, and ANB101 . Rosnilimab is an IgG1 antibody targeting pathogenic T cells for autoimmune and inflammatory diseases, having completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis (RA) . ANB033 is a CD122 antagonist in Phase 1b trials for celiac disease (CeD) and eosinophilic esophagitis (EoE) . ANB101 is a BDCA2 modulator antibody in a Phase 1a trial, targeting plasmacytoid dendritic cells (pDCs) for autoimmune and inflammatory diseases .

In terms of collaborative programs, AnaptysBio has an immuno-oncology collaboration with GSK for Jemperli (dostarlimab-gxly), a PD-1 antagonist antibody . Jemperli received FDA approval in April 2021 for advanced or recurrent deficient mismatch repair endometrial cancer (dMMREC), with full approval granted in February 2023 . A second FDA approval for Jemperli in pan-deficient mismatch repair tumors (PdMMRT) was received in August 2021 . In July 2023, the FDA approved Jemperli in combination with chemotherapy for dMMR MSI-H primary advanced or recurrent endometrial cancer, followed by EMA approval in December 2023 . August 2024 saw FDA approval for Jemperli plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, with EMA approval in January 2025 . GSK reported $1.1 billion in sales for Jemperli for the year ended December 31, 2025, representing greater than 80% sales growth compared to $598.0 million in 2024 . The company also has an exclusive license agreement with Vanda Pharmaceuticals Inc. for imsidolimab (IL-36R antagonist mAb), which has completed two registration-enabling global Phase 3 trials for generalized pustular psoriasis (GPP) . Vanda submitted a BLA for imsidolimab in GPP in December 2025, accepted by the FDA in February 2026 with a target action date of December 12, 2026 . Under the Vanda License Agreement, AnaptysBio received an upfront payment of $10.0 million and a $5.0 million payment for existing drug supply .

For the fiscal year ended December 31, 2025, AnaptysBio reported collaboration revenue of $234.6 million . Research and development expenses were $135.970 million , and general and administrative expenses were $50.737 million . The company incurred a net loss of $13.232 million , resulting in a basic and diluted EPS of $(0.46) . Non-cash interest expense for the sale of future royalties was $79.893 million , and interest income was $13.499 million . Cash and cash equivalents stood at $238.196 million , with short-term investments of $73.442 million and no long-term investments as of December 31, 2025. The total liability related to the sale of future royalties was $276.528 million .

Comparing fiscal year 2025 to 2024, collaboration revenue increased by $143.323 million, from $91.280 million in 2024 to $234.603 million in 2025 . This increase was driven by an $85.0 million increase in Jemperli sales milestones, a $48.6 million increase in Jemperli and Zejula royalty revenue, and a $9.7 million increase in Vanda license and transition services revenue . Research and development expenses decreased by $27.870 million, from $163.840 million in 2024 to $135.970 million in 2025 . This decrease was primarily due to a $21.6 million decrease in clinical expenses and a $12.0 million decrease in outside services for manufacturing expenses, partially offset by a $5.5 million increase in salaries and related costs . General and administrative expenses increased by $8.3 million, from $42.389 million in 2024 to $50.737 million in 2025 , mainly due to a $5.2 million increase in legal expenses and a $2.5 million increase in transaction costs related to the Vanda License Agreement . Non-cash interest expense for the sale of future royalties increased by $29.8 million, from $50.087 million in 2024 to $79.893 million in 2025 . Interest income decreased by $6.3 million, from $19.794 million in 2024 to $13.499 million in 2025 .

In September 2025, the company announced plans to explore separating its business into two independent, publicly traded companies: "Royalty Management Co" and "Biopharma Co" . In October 2025, GSK terminated the TIM-3 antagonist antibody development program under the existing collaboration, with all rights reverting to AnaptysBio . On November 20, 2025, AnaptysBio filed a Verified Complaint in Delaware Chancery Court against TESARO, Inc. and GSK, alleging material breach of the Collaboration Agreement and tortious interference, respectively .

Business Outlook

AnaptysBio expects to complete the proposed separation of its business into two independent, publicly traded companies in the second quarter of 2026 . Upon completion, the clinical-stage biotechnology company is intended to be launched with adequate capital to fund operations for at least twelve months after the separation date . The company anticipates the separation to be a taxable event and is focused on minimizing overall corporate and shareholder-level taxes .

The company's strategy includes enabling broad development of its autoimmunity and inflammation-focused portfolio, generating translational and clinical data to characterize its molecules and optimize development, innovating in clinical development and execution to achieve proof-of-concept and execute registrational studies, and facilitating global commercialization while retaining rights in key markets to become a fully integrated development and commercial organization . AnaptysBio also aims to continue leveraging its research expertise to identify, license, and innovate best-in-class antibodies against high-value immunological targets . A key strategic priority is maximizing return on equity through execution against a multi-year capital and operating plan, including managing and returning potential value from future royalty revenues from the GSK financial collaboration to shareholders .

The company expects its research and development expenses to be consistent for the foreseeable future as it continues to advance its product candidates . General and administrative expenses are expected to increase for the foreseeable future due to costs associated with stock compensation, legal, auditing, filing fees, additional insurance premiums, investor relations expenses, and general compliance and consulting expenses .

AnaptysBio believes that its existing cash, cash equivalents, and investments of $311.6 million as of December 31, 2025, will fund its current operating plan for at least the next twelve months from the issuance of its consolidated financial statements . The company may seek additional financing in the future through equity or debt financings or through collaborations or partnerships .

Risk Factors

Investing in AnaptysBio common stock involves a high degree of risk, including the potential for product candidates to fail or suffer delays in development, which could adversely affect their commercial viability . Results from initial clinical trials may not be representative of later-stage trials, and ongoing or planned trials may reveal significant adverse events, toxicities, or other side effects that could inhibit regulatory approval or market acceptance . The company and its collaborators may be unable to obtain or may be delayed in obtaining required regulatory approvals in the United States or foreign jurisdictions, materially impairing the ability to commercialize and generate revenue . Even if approved, products will be subject to significant post-marketing regulatory requirements . The company faces significant competition from major pharmaceutical and biotechnology companies with greater resources and expertise, which could negatively impact commercial opportunities if competitors develop more effective, safer, or less expensive products . Product candidates may not achieve adequate market acceptance among physicians, patients, and payors . The company currently lacks a marketing and sales force, and failure to establish effective capabilities or third-party agreements could hinder commercialization and revenue generation . Manufacturing biologics is complex, and third-party manufacturers may encounter production difficulties, delaying or stopping supply for clinical trials or commercialization . Political, economic, or public health events, including macroeconomic conditions like inflation, interest rate volatility, and geopolitical conflicts, may materially impact the U.S. and global economies, affecting the company's business, financial condition, and results of operations . The company has a history of operational losses and limited operating revenue, with no products approved for commercial sale, and may not achieve or sustain profitability . Additional capital will be required to finance operations, and if unavailable on acceptable terms, development and commercialization efforts may be incomplete . The proposed separation into two independent, publicly traded companies is subject to various risks and uncertainties, may not be completed as contemplated, and will involve significant time, effort, and expense . The existing collaboration with GSK and other collaborations are crucial, and inability to maintain them or their lack of success could adversely affect the business . Failure to establish additional development and commercialization collaborations could also adversely impact the ability to develop and commercialize product candidates . Inability to obtain or protect intellectual property rights in the U.S. and globally could impair competitive effectiveness . The company must attract and retain highly skilled employees to succeed . The market price of the stock has been and may continue to be volatile, leading to potential investment loss .

Management Priorities

Management's message to shareholders emphasizes the company's focus as a clinical-stage biotechnology company dedicated to delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. They highlight the ongoing clinical development of their wholly-owned pipeline, including rosnilimab, ANB033, and ANB101, and the revenue generation from out-licensed programs like Jemperli and imsidolimab. A key strategic priority is the proposed separation of the business into two independent, publicly traded companies, "Royalty Management Co" and "Biopharma Co," expected to be completed in the second quarter of 2026 . Management intends to launch the clinical-stage biotechnology company with adequate capital to fund operations for at least twelve months after the separation . They are focused on minimizing overall corporate and shareholder-level taxes related to this anticipated taxable event . Management believes that existing cash, cash equivalents, and investments of $311.6 million as of December 31, 2025, will fund the current operating plan for at least the next twelve months .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Rosnilimab
  6. [6] Item 1, Business — ANB033
  7. [7] Item 1, Business — ANB101
  8. [8] Item 1, Business — GSK Collaboration
  9. [9] Item 1, Business — GSK Collaboration
  10. [10] Item 1, Business — GSK Collaboration
  11. [11] Item 1, Business — GSK Collaboration
  12. [12] Item 1, Business — GSK Collaboration
  13. [13] Item 1, Business — GSK Collaboration
  14. [14] Item 1, Business — Vanda Collaboration
  15. [15] Item 1, Business — Vanda Collaboration
  16. [16] Item 1, Business — Vanda Collaboration
  17. [17] Item 7, MD&A — Results of Operations, Collaboration Revenue
  18. [18] Item 7, MD&A — Results of Operations, Research and Development Expenses
  19. [19] Item 7, MD&A — Results of Operations, General and Administrative Expenses
  20. [20] Item 7, MD&A — Results of Operations, Net loss
  21. [21] Item 7, MD&A — Results of Operations, Net loss per common share: Basic and diluted
  22. [22] Item 7, MD&A — Results of Operations, Non-Cash Interest Expense for the Sale of Future Royalties
  23. [23] Item 7, MD&A — Results of Operations, Interest Income
  24. [24] Item 7, MD&A — Liquidity and Capital Resources
  25. [25] Item 7, MD&A — Liquidity and Capital Resources
  26. [26] Item 7, MD&A — Liquidity and Capital Resources
  27. [27] Item 7, MD&A — Liquidity and Capital Resources
  28. [28] Item 7, MD&A — Results of Operations, Collaboration Revenue
  29. [29] Item 7, MD&A — Results of Operations, Collaboration Revenue
  30. [30] Item 7, MD&A — Results of Operations, Research and Development Expenses
  31. [31] Item 7, MD&A — Results of Operations, Research and Development Expenses
  32. [32] Item 7, MD&A — Results of Operations, General and Administrative Expenses
  33. [33] Item 7, MD&A — Results of Operations, General and Administrative Expenses
  34. [34] Item 7, MD&A — Results of Operations, Non-Cash Interest Expense for the Sale of Future Royalties
  35. [35] Item 7, MD&A — Results of Operations, Interest Income
  36. [36] Item 1, Business — Intention to Separate Company
  37. [37] Item 1, Business — GSK Collaboration
  38. [38] Item 3, Legal Proceedings
  39. [39] Item 1, Business — Intention to Separate Company
  40. [40] Item 1, Business — Intention to Separate Company
  41. [41] Item 1, Business — Intention to Separate Company
  42. [42] Item 1, Business — Our Strategy
  43. [43] Item 1, Business — Our Strategy
  44. [44] Item 1, Business — Our Strategy
  45. [45] Item 7, MD&A — Research and Development Expense
  46. [46] Item 7, MD&A — General and Administrative Expense
  47. [47] Item 7, MD&A — Liquidity and Capital Resources
  48. [48] Item 7, MD&A — Funding Requirements
  49. [49] Item 1A, Risk Factors — Summary of Risk Factors
  50. [50] Item 1A, Risk Factors — Summary of Risk Factors
  51. [51] Item 1A, Risk Factors — Summary of Risk Factors
  52. [52] Item 1A, Risk Factors — Summary of Risk Factors
  53. [53] Item 1A, Risk Factors — Summary of Risk Factors
  54. [54] Item 1A, Risk Factors — Summary of Risk Factors
  55. [55] Item 1A, Risk Factors — Summary of Risk Factors
  56. [56] Item 1A, Risk Factors — Summary of Risk Factors
  57. [57] Item 1A, Risk Factors — Summary of Risk Factors
  58. [58] Item 1A, Risk Factors — Summary of Risk Factors
  59. [59] Item 1A, Risk Factors — Summary of Risk Factors
  60. [60] Item 1A, Risk Factors — Summary of Risk Factors
  61. [61] Item 1A, Risk Factors — Summary of Risk Factors
  62. [62] Item 1A, Risk Factors — Summary of Risk Factors
  63. [63] Item 1A, Risk Factors — Summary of Risk Factors
  64. [64] Item 1A, Risk Factors — Summary of Risk Factors
  65. [65] Item 1A, Risk Factors — Summary of Risk Factors

Analysis on 5/19/2026